ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Washington, DC, USA:

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:Part A - first in human ...

Active, not recruiting
Multiple Sclerosis (MS)
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: ANK-700

Phase 1

Anokion

Vienna, Virginia, United States and 14 other locations

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Drug: Siponimod
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Washington, District of Columbia, United States and 72 other locations

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

Washington, District of Columbia, United States and 20 other locations

B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-ce...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Ocrelizumab

Phase 4

Johns Hopkins University
Johns Hopkins University

Baltimore, Maryland, United States

Locations recently updated

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a durat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Other: Fingolimod Placebo

Phase 3

Roche
Roche

Washington, District of Columbia, United States and 115 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Ofatumumab
Drug: Disease modifying treatment (DMT)

Phase 4

Novartis
Novartis

Lutherville, Maryland, United States and 32 other locations

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Fairfax, Virginia, United States and 122 other locations

A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Lutherville, Maryland, United States and 20 other locations

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Enrolling
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Washington, District of Columbia, United States and 39 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Bethesda, Maryland, United States and 152 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems